Dapagliflozin, a selective sglt2 inhibitor, improved glycemic control over 2 weeks in patients with type 1 diabetes mellitus

Category Primary study
JournalClinical Pharmacology and Therapeutics
Year 2014
This article has no abstract
Epistemonikos ID: ab5daf82ef0fa86b22b1e2ad5be33ff650f064b4
First added on: Jul 02, 2024